A systems-level “misunderstanding”: the plasma metabolome in Huntington's disease

Annals of Clinical and Translational Neurology

Volumn 2, Issue 7, 2015, Pages 756-768

  Rosas, Herminia D ^a,b   Doros, Gheorghe ^c   Bhasin, Swati ^d   Thomas, Beena ^d   Gevorkian, Sona ^a,b   Malarick, Keith ^a,b   Matson, Wayne ^d   Hersch, Steven M ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Center for Neuro imaging of Aging and Neurodegenerative Diseases   (United States)

^c BOSTON UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYANTHRANILIC ACID; 5 HYDROXYTRYPTOPHAN; ALPHA TOCOPHEROL; ANTIOXIDANT; ATROLACTIC ACID; BIOLOGICAL MARKER; GAMMA TOCOPHEROL; HOMOGENTISIC ACID; HOMOVANILLIC ACID; HUNTINGTIN; INDOLEPROPIONIC ACID; KYNURENINE; METHIONINE; N ACETYLSEROTONIN; N METHYLSEROTONIN; PURINE; SEROTONIN UPTAKE INHIBITOR; TRYPTOPHAN; TYROSINE; VANILMANDELIC ACID; XANTHINE; XANTHOSINE;

ADULT; AMINO ACID METABOLISM; AREA UNDER THE CURVE; ARTICLE; CELL DEATH; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; DISEASE COURSE; ELECTROCHEMICAL DETECTION; ENERGY TRANSFER; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; METABOLITE; METABOLOME; METABOLOMICS; MIDDLE AGED; NERVE DEGENERATION; OXIDATIVE STRESS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 84969409381     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.214     Document Type: Article

References (60)

1. Beal MF, Matson WR, Swartz KJ, et al. Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. J Neurochem 1990;55:1327–1339.
2. Stoy N, Mackay GM, Forrest CM, et al. Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J Neurochem 2005;93:611–623.
3. Pearson SJ, Reynolds GP. Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease. Neurosci Lett 1992;144:199–201.
4. Kristal BS, Shurubor YI, Kaddurah-Daouk R, Matson WR. Metabolomics in the study of aging and caloric restriction. Methods Mol Biol 2007;371:393–409.
5. Kristal BS, Shurubor YI, Kaddurah-Daouk R, Matson WR. High-performance liquid chromatography separations coupled with coulometric electrode array detectors: a unique approach to metabolomics. Methods Mol Biol 2007;358:159–174.
6. Kristal BS, Vigneau-Callahan KE, Matson WR. Simultaneous analysis of the majority of low-molecular-weight, redox-active compounds from mitochondria. Anal Biochem 1998;263:18–25.
7. Kristal BS, Vigneau-Callahan KE, Moskowitz AJ, Matson WR. Purine catabolism: links to mitochondrial respiration and antioxidant defenses? Arch Biochem Biophys 1999;370:22–33.
8. Schiavo S, Ebbel E, Sharma S, et al. Metabolite identification using a nanoelectrospray LC-EC-array-MS integrated system. Anal Chem 2008;80:5912–5923.
9. Shi H, Paolucci U, Vigneau-Callahan KE, et al. Development of biomarkers based on diet-dependent metabolic serotypes: practical issues in development of expert system-based classification models in metabolomic studies. OMICS 2004;8:197–208.
10. Shurubor YI, Matson WR, Willett WC, et al. Biological variability dominates and influences analytical variance in HPLC-ECD studies of the human plasma metabolome. BMC Clin Pathol 2007;7:9.
11. Paolucci U, Vigneau-Callahan KE, Shi H, et al. Development of biomarkers based on diet-dependent metabolic serotypes: concerns and approaches for cohort and gender issues in serum metabolome studies. OMICS 2004;8:209–220.
12. Rozen S, Cudkowicz ME, Bogdanov M, et al. Metabolomic analysis and signatures in motor neuron disease. Metabolomics 2005;1:101–108.
13. Bogdanov M, Matson WR, Wang L, et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008;131:389–396.
14. Johansen KK, Wang L, Aasly JO, et al. Metabolomic profiling in LRRK2-related Parkinson's disease. PLoS One 2009;4:e7551.
15. Kaddurah-Daouk R, Boyle SH, Matson W, et al. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl Psychiat 2011;1:e26.
16. Harrell FE. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. Springer series in statistics. New York, NY: Springer, 2001. pp. xxii, 568 p.
17. Steyerberg EW. SpringerLink (online service). In: Gail M., Samet J.M., Tsiatis A., Wong W. eds. Statistics for biology and health. New York, NY: Springer, 2009. pp. xxviii, 497 p.
18. Efron B. How biased is the apparent error rate of a prediction rule? J Am Stat Assoc 1986;81:461–470.
19. Wikoff WR, Anfora AT, Liu J, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci USA 2009;106:3698–3703.
20. Vaarala O, Atkinson MA, Neu J. The “perfect storm” for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 2008;57:2555–2562.
21. King C, Sarvetnick N. The incidence of type-1 diabetes in NOD mice is modulated by restricted flora not germ-free conditions. PLoS One 2011;6:e17049.
22. Soulet D, Cicchetti F. The role of immunity in Huntington's disease. Mol Psychiatry 2011;16:889–902.
23. De Ponti F. Drug development for the irritable bowel syndrome: current challenges and future perspectives. Front Pharmacol 2013;4:7.
24. Politis M, Su P, Piccini P. Imaging of microglia in patients with neurodegenerative disorders. Front Pharmacol 2012;3:96.
25. Bjorkqvist M, Wild EJ, Thiele J, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med 2008;205:1869–1877.
26. Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science 2012;336:1262–1267; published online EpubJun 8.
27. Resta SC. Effects of probiotics and commensals on intestinal epithelial physiology: implications for nutrient handling. J Physiol 2009;587:4169–4174.
28. Pauley RJ, Fredricks WW, Smith OH. Effect of tryptophan analogs on derepression of the Escherichia coli tryptophan operon by indole-3-propionic acid. J Bacteriol 1978;136:219–226.
29. Chyan YJ, Poeggeler B, Omar RA, et al. Potent neuroprotective properties against the Alzheimer beta-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid. J Biol Chem 1999;274:21937–21942.
30. Karbownik M, Reiter RJ, Garcia JJ, et al. Indole-3-propionic acid, a melatonin-related molecule, protects hepatic microsomal membranes from iron-induced oxidative damage: relevance to cancer reduction. J Cell Biochem 2001;81:507–513.
31. Bendheim PE, Poeggeler B, Neria E, et al. Development of indole-3-propionic acid (OXIGON) for Alzheimer's disease. J Mol Neurosci 2002;19:213–217.
32. Coyle JT, Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 1976;263:244–246.
33. Thevandavakkam MA, Schwarcz R, Muchowski PJ, Giorgini F. Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease. CNS Neurol Disord Drug Targets 2010;9:791–800.
34. Zwilling D, Huang SY, Sathyasaikumar KV, et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 2011;145:863–874.
35. Beal MF, Matson WR, Storey E, et al. Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex. J Neurol Sci 1992;108:80–87.
36. Zhou H, Wang J, Jiang J, et al. N-acetyl-serotonin offers neuroprotection through inhibiting mitochondrial death pathways and autophagic activation in experimental models of ischemic injury. J Neurosci 2014;34:2967–2978.
37. Cardinali DP, Pagano ES, Scacchi Bernasconi PA, et al. Melatonin and mitochondrial dysfunction in the central nervous system. Horm Behav 2013;63:322–330.
38. Aziz NA, Pijl H, Frolich M, et al. Delayed onset of the diurnal melatonin rise in patients with Huntington's disease. J Neurol 2009;256:1961–1965.
39. Christofides J, Bridel M, Egerton M, et al. Blood 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and melatonin levels in patients with either Huntington's disease or chronic brain injury. J Neurochem 2006;97:1078–1088.
40. Mohamed Mel S, Ismail W, Heider J, Fuchs G. Aerobic metabolism of phenylacetic acids in Azoarcus evansii. Arch Microbiol 2002;178:180–192.
41. Mu W, Yang Y, Jia J, et al. Production of 4-hydroxyphenyllactic acid by Lactobacillus sp. SK007 fermentation. J Biosci Bioeng 2010;109:369–371.
42. Petersen M, Abdullah Y, Benner J, et al. Evolution of rosmarinic acid biosynthesis. Phytochemistry 2009;70:1663–1679. doi: 10.1016/j.phytochem.2009.05.010; published online Epub Oct-Nov.
43. Beloborodova N, Bairamov I, Olenin A, et al. Effect of phenolic acids of microbial origin on production of reactive oxygen species in mitochondria and neutrophils. J Biomed Sci 2012;19:89.
44. Kayden HJ, Traber MG. Absorption, lipoprotein transport, and regulation of plasma concentrations of vitamin E in humans. J Lipid Res 1993;34:343–358.
45. Hughes PE, Tove SB. Occurrence of alpha-tocopherolquinone and alpha-tocopherolquinol in microorganisms. J Bacteriol 1982;151:1397–1402.
46. Cani PD, Delzenne NM. The gut microbiome as therapeutic target. Pharmacol Ther 2011;130:202–212.
47. Sternberg DE, Heninger GR, Roth RH. Plasma homovanillic acid as an index of brain dopamine metabolism: enhancement with debrisoquin. Life Sci 1983;32:2447–2452.
48. Amin F, Davidson M, Davis KL. Homovanillic acid measurement in clinical research: a review of methodology. Schizophr Bull 1992;18:123–148.
49. Russo S, Kema IP, Bosker F, et al. Tryptophan as an evolutionarily conserved signal to brain serotonin: molecular evidence and psychiatric implications. World J Biol Psychiatry 2009;10:258–268.
50. Russo S, Kema IP, Haagsma EB, et al. Irritability rather than depression during interferon treatment is linked to increased tryptophan catabolism. Psychosom Med 2005;67:773–777.
51. Kurlan R, Goldblatt D, Zaczek R, et al. Cerebrospinal fluid homovanillic acid and parkinsonism in Huntington's disease. Ann Neurol 1988;24:282–284.
52. Ziegler MG, Kennedy B, Holland OB, et al. The effects of dopamine agonists on human cardiovascular and sympathetic nervous systems. Int J Clin Pharmacol Ther Toxicol 1985;23:175–179.
53. Norman TR, Chiu E, French MA. Platelet monoamine oxidase activity in patients with Huntington's disease. Clin Exp Pharmacol Physiol 1987;14:547–550.
54. Ascherio A, LeWitt PA, Xu K, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009;66:1460–1468.
55. Schwarzschild MA, Schwid SR, Marek K, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 2008;65:716–723.
56. Parkinson Study Group S.-P. D. I., Schwarzschild MA, Ascherio A, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol 2014;71:141–150.
57. Chen X, Wu G, Schwarzschild MA. Urate in Parkinson's disease: more than a biomarker? Curr Neurol Neurosci Rep 2012;12:367–375. doi: 10.1007/s11910-012-0282-7; published online Epub Aug.
58. Thomas B, Matson S, Chopra V, et al. A novel method for detecting 7-methyl guanine reveals aberrant methylation levels in Huntington disease. Anal Biochem 2013;436:112–120.
59. Fox JH, Connor T, Stiles M, et al. Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein. J Biol Chem 2011;286:18320–18330.
60. Matson W; U. S. Patents, ed. Method of diagnosing or categorizing disorders from biochemical profiles. 2001.